CN105130936B - 一类邻萘醌化合物、其制备方法和医药用途 - Google Patents
一类邻萘醌化合物、其制备方法和医药用途 Download PDFInfo
- Publication number
- CN105130936B CN105130936B CN201510553148.2A CN201510553148A CN105130936B CN 105130936 B CN105130936 B CN 105130936B CN 201510553148 A CN201510553148 A CN 201510553148A CN 105130936 B CN105130936 B CN 105130936B
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- 300mhz
- nmr
- cdcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 naphthoquinone compound Chemical class 0.000 title claims abstract description 31
- 229930192627 Naphthoquinone Natural products 0.000 title claims abstract description 6
- 238000002360 preparation method Methods 0.000 title claims description 84
- 150000001875 compounds Chemical class 0.000 claims abstract description 168
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 92
- 229910003827 NRaRb Inorganic materials 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 150000002390 heteroarenes Chemical class 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229950002366 nafoxidine Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000005936 piperidyl group Chemical group 0.000 claims description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims 1
- XWINCPYLXQTPQV-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1.C1CNCCN1 XWINCPYLXQTPQV-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 69
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 abstract description 16
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 abstract description 16
- 230000000259 anti-tumor effect Effects 0.000 abstract description 14
- 230000002829 reductive effect Effects 0.000 abstract description 11
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 5
- 102100034576 Quinone oxidoreductase Human genes 0.000 abstract description 4
- 101710157142 2-methylene-furan-3-one reductase Proteins 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 3
- 101710189291 Quinone oxidoreductase Proteins 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 144
- 238000005160 1H NMR spectroscopy Methods 0.000 description 76
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 64
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- 238000006243 chemical reaction Methods 0.000 description 63
- 239000007787 solid Substances 0.000 description 47
- 239000000243 solution Substances 0.000 description 42
- 150000002240 furans Chemical class 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 238000001035 drying Methods 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 14
- 239000011734 sodium Substances 0.000 description 13
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 11
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 10
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 10
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 8
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical group NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 4
- SDJHPPZKZZWAKF-UHFFFAOYSA-N 2,3-dimethylbuta-1,3-diene Chemical compound CC(=C)C(C)=C SDJHPPZKZZWAKF-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
- 229940049706 benzodiazepine Drugs 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 3
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 3
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 3
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 3
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 3
- GQYLQOBVKLBZPU-UHFFFAOYSA-N 1,2,6-trimethylnaphthalene Chemical class CC1=C(C)C=CC2=CC(C)=CC=C21 GQYLQOBVKLBZPU-UHFFFAOYSA-N 0.000 description 3
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 3
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 0 Cc(cc1-c([o]c(I*)*2*)c2C2=O)c(C)cc1C2=O Chemical compound Cc(cc1-c([o]c(I*)*2*)c2C2=O)c(C)cc1C2=O 0.000 description 3
- 102100030497 Cytochrome c Human genes 0.000 description 3
- 108010075031 Cytochromes c Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- QNLZIZAQLLYXTC-UHFFFAOYSA-N dimethylnaphthalene Natural products C1=CC=CC2=C(C)C(C)=CC=C21 QNLZIZAQLLYXTC-UHFFFAOYSA-N 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000004053 quinones Chemical class 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- DIXMBHMNEHPFCX-MCMMXHMISA-N (2r)-2-[5-[6-amino-5-[(1r)-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]pyridin-3-yl]-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol Chemical compound O([C@H](C)C=1C(=CC=C(F)C=1)N1N=CC=N1)C(C(=NC=1)N)=CC=1C=1SC([C@](C)(O)CO)=NC=1C DIXMBHMNEHPFCX-MCMMXHMISA-N 0.000 description 2
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical class O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 2
- 229940005561 1,4-benzoquinone Drugs 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
- OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 description 2
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical group NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 2
- ZRXHLJNBNWVNIM-UHFFFAOYSA-N 3-methyl-1-benzofuran Chemical class C1=CC=C2C(C)=COC2=C1 ZRXHLJNBNWVNIM-UHFFFAOYSA-N 0.000 description 2
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical group OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000003939 benzylamines Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- CIEYTVIYYGTCCI-UHFFFAOYSA-N lapachol Chemical compound C1=CC=C2C(=O)C(CC=C(C)C)=C(O)C(=O)C2=C1 CIEYTVIYYGTCCI-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 150000002780 morpholines Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 2
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 2
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- HPJGEESDHAUUQR-SKGSPYGFSA-N (2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]buta Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)CCC=1C=NC=CC=1)CC1=CC=CC=C1 HPJGEESDHAUUQR-SKGSPYGFSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 1
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 1
- AVJKDKWRVSSJPK-UHFFFAOYSA-N 1-(4-fluorophenyl)piperazine Chemical group C1=CC(F)=CC=C1N1CCNCC1 AVJKDKWRVSSJPK-UHFFFAOYSA-N 0.000 description 1
- MTGMPCZPBVBDBK-UHFFFAOYSA-N 1-chloroethenesulfonic acid Chemical group OS(=O)(=O)C(Cl)=C MTGMPCZPBVBDBK-UHFFFAOYSA-N 0.000 description 1
- KQCMTOWTPBNWDB-UHFFFAOYSA-N 2,4-dichloroaniline Chemical group NC1=CC=C(Cl)C=C1Cl KQCMTOWTPBNWDB-UHFFFAOYSA-N 0.000 description 1
- CEPCPXLLFXPZGW-UHFFFAOYSA-N 2,4-difluoroaniline Chemical group NC1=CC=C(F)C=C1F CEPCPXLLFXPZGW-UHFFFAOYSA-N 0.000 description 1
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical group OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical group OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- SDYWXFYBZPNOFX-UHFFFAOYSA-N 3,4-dichloroaniline Chemical group NC1=CC=C(Cl)C(Cl)=C1 SDYWXFYBZPNOFX-UHFFFAOYSA-N 0.000 description 1
- ARHQTVVPMKKQAL-UHFFFAOYSA-N 3,7,8-trimethylnaphthalene-2-carbonyl chloride Chemical class ClC(=O)C1=CC2=C(C(=CC=C2C=C1C)C)C ARHQTVVPMKKQAL-UHFFFAOYSA-N 0.000 description 1
- XQHXMPSNRXWOIS-UHFFFAOYSA-N 3,7,8-trimethylnaphthalene-2-sulfonyl chloride Chemical class ClS(=O)(=O)C1=CC2=C(C(=CC=C2C=C1C)C)C XQHXMPSNRXWOIS-UHFFFAOYSA-N 0.000 description 1
- JXOFSSIWAOYVSJ-UHFFFAOYSA-N 3-butyl-1-benzofuran Chemical class C1=CC=C2C(CCCC)=COC2=C1 JXOFSSIWAOYVSJ-UHFFFAOYSA-N 0.000 description 1
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 1
- OVDGUTHABMXVMI-UHFFFAOYSA-N 3-nitro-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1[N+]([O-])=O OVDGUTHABMXVMI-UHFFFAOYSA-N 0.000 description 1
- KMHLGVTVACLEJE-UHFFFAOYSA-N 4-fluoro-2-methylaniline Chemical group CC1=CC(F)=CC=C1N KMHLGVTVACLEJE-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical group NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- DRDICBKYBXLQHQ-UHFFFAOYSA-N 6-butyl-1,2-dimethylnaphthalene Chemical class C(CCC)C=1C=CC2=C(C(=CC=C2C=1)C)C DRDICBKYBXLQHQ-UHFFFAOYSA-N 0.000 description 1
- HPEKUTKPEHUOGM-UHFFFAOYSA-N 6-butyl-7-(chloromethyl)-1,2-dimethylnaphthalene Chemical class ClCC1=CC2=C(C(=CC=C2C=C1CCCC)C)C HPEKUTKPEHUOGM-UHFFFAOYSA-N 0.000 description 1
- RTDSEBKDJNMRNM-UHFFFAOYSA-N 6-ethyl-1,2-dimethylnaphthalene Chemical class CC1=C(C)C=CC2=CC(CC)=CC=C21 RTDSEBKDJNMRNM-UHFFFAOYSA-N 0.000 description 1
- XXIYDUDCRQDIRA-UHFFFAOYSA-N 7-(chloromethyl)-1,2,6-trimethylnaphthalene Chemical class ClCC1=CC2=C(C(=CC=C2C=C1C)C)C XXIYDUDCRQDIRA-UHFFFAOYSA-N 0.000 description 1
- RHLJLXQKNIVVCV-UHFFFAOYSA-N 7-(chloromethyl)-6-ethyl-1,2-dimethylnaphthalene Chemical class ClCC1=CC2=C(C(=CC=C2C=C1CC)C)C RHLJLXQKNIVVCV-UHFFFAOYSA-N 0.000 description 1
- MWCDTFPBCWBTOS-UHFFFAOYSA-N 7-(chloromethylsulfonyl)-1,2,6-trimethylnaphthalene Chemical class ClCS(=O)(=O)C1=CC2=C(C(=CC=C2C=C1C)C)C MWCDTFPBCWBTOS-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- YMTYCVQRGARUTH-UHFFFAOYSA-N CCCCCCCCCCCCCC[ClH]CC1=CC(C)=CC2=CC=C(C)C(C)=C12 Chemical class CCCCCCCCCCCCCC[ClH]CC1=CC(C)=CC2=CC=C(C)C(C)=C12 YMTYCVQRGARUTH-UHFFFAOYSA-N 0.000 description 1
- RLJFYGAVNLVESD-UHFFFAOYSA-N C[O]=C(C=C1)C=CC1=O Chemical compound C[O]=C(C=C1)C=CC1=O RLJFYGAVNLVESD-UHFFFAOYSA-N 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- DHOAKZPBYPWBQI-UHFFFAOYSA-N Cc(cc1-c2c(C3=O)nc(CCl)[o]2)c(C)cc1C3=O Chemical compound Cc(cc1-c2c(C3=O)nc(CCl)[o]2)c(C)cc1C3=O DHOAKZPBYPWBQI-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical group ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 235000004237 Crocus Nutrition 0.000 description 1
- 241000596148 Crocus Species 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- PZUSGRHVYDQLHR-UHFFFAOYSA-N Fc1cc2C(=O)c3nc(C#N)c(nc3-c2cc1F)C#N Chemical compound Fc1cc2C(=O)c3nc(C#N)c(nc3-c2cc1F)C#N PZUSGRHVYDQLHR-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- MEPSBMMZQBMKHM-UHFFFAOYSA-N Lomatiol Natural products CC(=C/CC1=C(O)C(=O)c2ccccc2C1=O)CO MEPSBMMZQBMKHM-UHFFFAOYSA-N 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 1
- IHXKXSJKLJZXKZ-UHFFFAOYSA-N NC(C(C=C1)=O)=CC1=O Chemical compound NC(C(C=C1)=O)=CC1=O IHXKXSJKLJZXKZ-UHFFFAOYSA-N 0.000 description 1
- XHPUADDSMWCJDB-UHFFFAOYSA-N O=C(C=Cc1c2nc(CCl)[o]1)C2=O Chemical compound O=C(C=Cc1c2nc(CCl)[o]1)C2=O XHPUADDSMWCJDB-UHFFFAOYSA-N 0.000 description 1
- UPPYOQWUJKAFSG-UHFFFAOYSA-N Oc(cc1)cc2c1[o]cn2 Chemical compound Oc(cc1)cc2c1[o]cn2 UPPYOQWUJKAFSG-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- ROFVXGGUISEHAM-UHFFFAOYSA-N URB597 Chemical compound NC(=O)C1=CC=CC(C=2C=C(OC(=O)NC3CCCCC3)C=CC=2)=C1 ROFVXGGUISEHAM-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000004054 benzoquinones Chemical class 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- FBSMERQALIEGJT-UHFFFAOYSA-N chlorpromazine hydrochloride Chemical group [H+].[Cl-].C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 FBSMERQALIEGJT-UHFFFAOYSA-N 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- KNOSIOWNDGUGFJ-UHFFFAOYSA-N hydroxysesamone Natural products C1=CC(O)=C2C(=O)C(CC=C(C)C)=C(O)C(=O)C2=C1O KNOSIOWNDGUGFJ-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001967 indiganyl group Chemical group [H][In]([H])[*] 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- SIUGQQMOYSVTAT-UHFFFAOYSA-N lapachol Natural products CC(=CCC1C(O)C(=O)c2ccccc2C1=O)C SIUGQQMOYSVTAT-UHFFFAOYSA-N 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical group COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- BGXZIBSLBRKDTP-UHFFFAOYSA-N methyl 9-(4-chloroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Cl)C=C1 BGXZIBSLBRKDTP-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- PHHRKRGXWSEXFZ-UHFFFAOYSA-N n-(pyridin-3-ylmethyl)-3-[[2-[(2,3,4-trifluorophenoxy)methyl]-1,3-benzoxazol-4-yl]oxy]propan-1-amine Chemical compound FC1=C(F)C(F)=CC=C1OCC(OC1=CC=C2)=NC1=C2OCCCNCC1=CC=CN=C1 PHHRKRGXWSEXFZ-UHFFFAOYSA-N 0.000 description 1
- PHVXTQIROLEEDB-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]-4-[[3-(2-methylphenyl)piperidin-1-yl]methyl]-n-pyrrolidin-3-ylbenzamide Chemical compound CC1=CC=CC=C1C1CN(CC=2C=CC(=CC=2)C(=O)N(CCC=2C(=CC=CC=2)Cl)C2CNCC2)CCC1 PHVXTQIROLEEDB-UHFFFAOYSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- QEZIFBAXJMHDJP-UHFFFAOYSA-N n-chloro-4-fluoroaniline Chemical class FC1=CC=C(NCl)C=C1 QEZIFBAXJMHDJP-UHFFFAOYSA-N 0.000 description 1
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 1
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical group COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical group COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 150000003053 piperidines Chemical group 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003233 pyrroles Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- KCDXJAYRVLXPFO-UHFFFAOYSA-N syringaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1O KCDXJAYRVLXPFO-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical group CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及药物化学领域,具体涉及一类具有抗肿瘤活性的邻萘醌化合物,包括这些化合物制备方法,这些化合物在分子水平可以被还原型辅酶I:醌氧化还原酶(NQO1)活化,在细胞水平和动物水平均表现出较良的抗肿瘤作用,可用于制备抗肿瘤药物。
Description
技术领域
本发明涉及药物化学领域,具体涉及一类具有抗肿瘤活性的邻萘醌化合物,包括这些化合物制备方法,这些化合物在分子水平可以被还原型辅酶I:醌氧化还原酶(NQO1)活化,在细胞水平和动物水平均表现出较良的抗肿瘤作用,可用于制备抗肿瘤药物。
背景技术
目前人们在利用小分子来抗肿瘤的策略中,主要需要考虑的是在选择性地杀死肿瘤细胞的同时,而不会对正常组织带来损伤。为了提高药物选择性,我们在设计药物的时候更需要关注肿瘤细胞与正常细胞在生化和生理过程的区别。其中之一的方法就是基于生物还原激活的途径,利用肿瘤细胞中具有高表达的还原酶这一特征,而达到选择性抑制肿瘤的作用。Workman和Walton于1989年首次提出了基于生物还原酶的靶向药物的概念,以在肿瘤细胞中高表达的生物还原酶为靶点,通过对底物进行还原从而选择性地杀死相应的肿瘤细胞。而醌氧化还原酶(NQO1)就是其中被广泛作为选择性抗肿瘤的还原代谢酶。很多实体瘤中都含有高表达的NQO1,并且NQO1酶自身具有可以生物激活许多醌抗肿瘤试剂的特点。因此,基于生物双电子还原代谢酶NQO1的抗肿瘤作用成为最近研究的热点。
而很多邻醌化合物都具有细胞毒性,可作为抗肿瘤药物。例如之前报道的丹参酮IIA、隐丹参酮或β-拉帕醌等邻醌类化合物都对肿瘤细胞A549显示出了一定抑制活性。而最近有文献报道该类型的邻醌类化合物可作为NQO1酶的底物,在NQO1酶的介导下通过产生活性氧的方法,选择性的杀死肿瘤细胞。该类邻醌类化合物能够在NQO1高表达的肿瘤细胞中快速、大量的被还原代谢为邻二酚产物,后者在细胞氧分子作用下发生自氧化重新转变为醌底物,形成氧化还原循环,而这一氧化还原循环过程将产生大量的活性氧。高浓度的活性氧将严重破坏肿瘤细胞的氧化还原微环境平衡,产生氧化应激,进而通过多种途径如降低线粒体的膜电位、激活Caspase-3凋亡通路或直接破坏DNA功能等诱导肿瘤细胞凋亡,发挥选择性抗肿瘤作用。
发明内容
本发明通过对丹参酮IIA的结构剖析,在保留天然产物丹参酮IIA分子抗肿瘤作用的关键邻醌骨架基础上,首次构建了二甲基萘邻醌化合物骨架,并引入一系列侧链,合成了一类丹参酮IIA衍生物。本发明的化合物具有与丹参酮IIA相当的抗肿瘤活性,并且在选择性上明显优于丹参酮IIA,有望开发成抗肿瘤药物。
本发明的邻萘醌化合物具有通式I所示的结构:
其中X代表碳原子或氮原子;当X为氮原子时,R1无取代;当X为碳原子时,R1为氢、或C1~C4烷基;
L代表-(CH2)n-、-CO(CH2)n-或-SO2(CH2)n-,其中n代表0~2;
R2代表氢、甲基、C1~C4烷氧基、-NRaRb、或m代表0或1;Ar代表苯环及或5~6员芳杂环;R4代表氢、卤素、氰基、硝基、甲氧基、C1~C4烷基、-NRaRb或-CH2-NRaRb;
上述-NRaRb中的Ra、Rb各自独立代表氢、C1~C4烷基、C1~C4羟烷基或Ra、Rb连接形成5~6员含氮杂环。
当X为碳原子;R1优选代表甲基。
L优选代表键、-CH2-、-CO-、-COCH2-或-SO2-。
R2优选代表氢、-NRaRb、其中Ra、Rb、m、R4定义同权利要求1。
R2代表-NRaRb时,Ra、Rb优选各自独立代表氢、甲基、乙基、丙基、异丙基、正丁基;或者还优选Ra、Rb连接形成四氢吡咯基、哌啶基、吗啡啉基、哌嗪基或N-甲基哌嗪基。
本发明部分化合物的代号及化学结构如下:
本发明的化合物可以用下列方法制备:
通式I化合物的制备:
其中X、R1、R2、L的定义同前。
化合物III与1,4-丁二烯反应得到化合物IV,反应温度优选80~150℃,反应时间优选为12~24h,反应溶剂优选甲苯、苯、DMF、二甲苯等。反应中还应加入2,3-二氯-5,6-二氰基-1,4苯醌。
化合物IV与二卤代烷、卤代酰氯或卤代磺酰氯反应生成V,反应温度为40~60℃,反应时间优选为4-12h,反应溶剂为乙酸乙酯、DMF、二氯甲烷、丙酮等。反应中还应加入无机碱或有机碱,如氢氧化钠、氢氧化钾、碳酸钾、碳酸钠、三乙胺等。
化合物V与取代的或无取代的酚、脂肪胺或芳香胺或其他的亲和试剂反应得到目标物I,反应温度为20~60℃,反应时间为2~8h,反应溶剂可选DMF、乙腈、丙酮、四氢呋喃、二氯甲烷等。反应中还应加入无机碱或有机碱,如氢氧化钠、氢氧化钾、碳酸钾、碳酸钠、三乙胺等。
通式I化合物可以采用常见的分离方法进行纯化,如重结晶、柱层析等。
本发明也包括通式I化合物的水合物、立体异构体、溶剂化物和药学上可接受的盐等。它们具有与通式I化合物同样的药理活性。
本发明所述的化合物可以添加药学上可接受的载体制成常见的药用制剂,如片剂、胶囊、粉剂、糖浆、液剂、悬浮剂、针剂,可以加入香料、甜味剂、液体或固体填料或稀释剂等常用药用辅料。
本发明的优点在于:无需采用分离自天然产物的丹参酮IIA作为原料加以修饰,可以直接通过合成得到;结构新颖;其抗肿瘤活性优于丹参酮IIA或与其相当;且该类化合物为双电子氧化还原酶NQO1的底物,其被NQO1酶代谢速率优于丹参酮IIA;本发明化合物的成药性明显优于丹参酮IIA,有望开发成为抗肿瘤药物。
本发明的化合物临床所用剂量为0.01mg~1000mg/天,也可根据病情的轻重或剂型的不同偏离此范围。
以下是本发明部分化合物的药理学试验及结果:
(1)化合物被NQO1还原代谢速率的测定:
实验方法:利用NADPH在酶NQO1(EC 1.6.5.5,Sigma购买)及醌化合物的存在下,会被氧化为NADP+,这一过程会导致在340nm下的吸光值发生变化(通过Varioskan Flash监控)。首先将化合物与酶在37℃下孵育,当NADPH加进去之后开始反应,3分钟之内动态检测发光330nm的变化。还原速率记为μmol NADPH/min/μmol NQO1.
表1 本发明部分化合物对NQO1酶的代谢速率
(2)化合物对肿瘤细胞的毒性的测定
实验方法:采用MTT染色法(Cancer Research 47(1987)936-942),培养时间为72小时。在96孔板中分别以3.0×103/well接种,每一个化合物设六个梯度,每一浓度设三复孔。用酶标仪,在波长560nm条件下测定光密度值(OD)。以溶剂对照处理的肿瘤细胞为对照组,用Grappad Prism 6软件计算IC50。
表2 本发明部分化合物对NQO1高表达的肿瘤细胞A549的抑制作用(IC50:μM)a:
化合物编号 | IC50(μM) | 化合物编号 | IC50(μM) |
CPUYB001 | 15±2.9 | CPUYB018 | 3.5±1.3 |
CPUYB002 | 12±3.9 | CPUYB019 | 2.8±0.7 |
CPUYB003 | 9.1±2.1 | CPUYB022 | 8.9±3.2 |
CPUYB004 | 4.8±1.9 | CPUYB025 | 11±4.6 |
CPUYB005 | 5.3±2.5 | CPUYB026 | 2.2±1.2 |
CPUYB006 | 5.3±2.5 | CPUYB029 | 3.1±2.9 |
CPUYB007 | 8.4±1.8 | CPUYB030 | 4.1±3.4 |
CPUYB009 | 11±1.5 | CPUYB032 | 5.6±1.2 |
CPUYB010 | 23±8.8 | CPUYB033 | 7.8±2.2 |
CPUYB011 | 14±4.3 | CPUYB035 | 11±7.7 |
CPUYB012 | 11±3.9 | CPUYB036 | 3.6±1.9 |
CPUYB013 | 8.5±3.1 | CPUYB038 | 4.9±2.3 |
CPUYB014 | 4.1±2.2 | CPUYB044 | 12±4.8 |
CPUYB015 | 16±3.1 | 丹参酮IIA | 4.7±1.0 |
CPUYB017 | 2.1±0.9 |
aA549:人肺癌细胞
由表2可见,本发明的化合物具有较强的抗肿瘤细胞增殖的活性,其活性优于丹参酮IIA或与其相当。
(3)化合物通过增加活性氧产生的机制达到抗肿瘤作用
实验方法:1、从酶水平检验化合物产生活性氧的水平。采用细胞色素c检测活性氧的生成,细胞色素c在550nm下具有吸收光,被氧化后其吸收光消失。根据细胞色素c量的变化判断化合物产生活性氧的能力。
表3 本发明部分化合物在酶水平产生活性氧的速率:
2、从细胞水平(静脉内)评价化合物产生活性氧的能力。采用sigma生产的DCFH-DA试剂盒,利用NQO1高表达的肺癌肿瘤细胞,检测化合物是否可以提高肿瘤细胞中的ROS水平,从而破坏肿瘤细胞的氧化还原平衡,达到抗肿瘤作用。DCFH-DA试剂盒是一种利用荧光探针DCFH-DA进行活性氧检测的试剂盒。DCFH-DA本身没有荧光,可以自由穿过细胞膜,进入细胞内后,可以被细胞内的酯酶水解生成DCFH。而DCFH不能通透细胞膜,从而使探针很容易被装载到细胞内。细胞内的活性氧可以氧化无荧光的DCFH生成有荧光的DCF。检测DCF的荧光就可以知道细胞内活性氧水平。图1为代表性化合物对A549肿瘤细胞内活性提高的倍数(相对于空白DMSO)。
由表3和图1可见,本发明的化合物通过产生ROS达到抗肿瘤作用,其产生ROS的能力优于天然产物丹参酮IIA.
(4)体内抗肿瘤活性研究
实验方法:收集生长旺盛期人肺腺癌细胞,在无菌条件下制备成细胞悬液,接种于裸小鼠腋下。裸小鼠移植瘤用游标卡尺测量移植瘤直径,待肿瘤生长至一定大小后将动物分组,每组5只。使用测量瘤径的方法,动态观察被试物抗肿瘤的效应。空白对照给予等剂量羟丙基-β-环糊精;化合物组:尾静脉注射,隔天一次,持续21天。21天后处死荷瘤裸鼠,并分离瘤块称重。所得数据进行统计学处理(t检验),计算抑瘤率。同时,对最终剥离的瘤块拍照保存图片。
表4 本发明代表性化合物的A549移植瘤的生长抑制率
由表4可见,本发明的代表性化合物CPUYB030对小鼠移植瘤A549的具有很好的抑制作用,与二期临床药物拉帕醌具有相当的抑制活性。
附图说明
图1为代表性化合物对A549肿瘤细胞内活性提高的倍数
具体实施方式
实施例1
通式I化合物合成路线(A系列化合物的合成):
(E)-4-(丙-1-烯基)吗啉(3a)的制备
将吗啉(26mL,0.294mol)和无水碳酸钾(2.0g,14.7mmol)置于250mL的三颈瓶中,加入搅拌子。在氮气保护,0℃冰浴下搅拌。当溶液温度降至0℃后,采用注射器慢慢注入丙醛(9mL,0.125mol)。加入丙醛时一定要缓慢,时刻注意温度的变化,丙醛一般要求约1小时内加完。加入完毕后,反应物继续在冰浴下搅拌2小时。反应到规定时间后,将反应液过滤,滤除固体,并用乙醚润洗固体。将滤液进行旋转蒸发除去低沸点的物质,然后将剩余物质进行减压蒸馏b.p.88-90℃/25mmHg,获得无色油状液体(7.0g,45%)。1H NMR(300MHz,DMSO)δ:5.83(d,1H,J=15Hz),4.38(dq,1H,J=12Hz,9Hz),3.58-3.50(m,4H),2.85-2.75(m,2H),2.52-2.44(m,2H),1.60-1.53(m,3H);m/z(EI-MS):127[M]+。
3-甲基-2-吗啉基-5-羟基-2,3-二氢苯并[1,2-b]呋喃(4a)的制备
将对苯醌(5.0g,46.3mmol)用150mL无水二氯甲烷溶解,并置于冰盐浴下冷却至-5℃。事先将蒸馏出来的3a(5.9g,46.3mmol)用无水的二氯甲烷(50mL)溶解,同样置于冰盐浴下冷却至-5℃。在氮气保护下,用注射器取已冷却的(E)-4-(丙-1-烯基)吗啉溶液逐滴加入同样已冷却的对苯醌溶液中。在滴加的过程中,溶液逐渐变为酒红色,这是正常现象。该酒红色的溶液在冰浴下0℃继续搅拌3小时,接着再室温搅拌过夜。反应完成后,过滤出固体产物,用二氯甲烷(2×10mL)洗涤,烘干后得目标产物,为白色絮状固体(4.0g,30%)。此步粗产物不用进一步纯化,可直接用于下步反应。
3-甲基-5-羟基苯并[1,2-b]呋喃(5a)的制备
4a(4.0g,17.0mmol)溶于20mL四氢呋喃中,将稀盐酸(5%,90mL)滴加到反应液中。反应液回流2h,冷却后用乙酸乙酯(3×30mL)萃取,无水硫酸钠干燥,减压除去溶剂后,用二氯甲烷重结晶,最后得白色晶体(2.0g,79.5%)。m.p.145-147℃,1H NMR(300MHz,CDCl3)δ:7.35(s,1H),7.28(d,J=8.8Hz,1H),6.90(d,J=2.7Hz,1H),6.77(dd,J=8.8,2.7Hz,1H),4.84(s,1H),2.17(s,3H);m/z(EI-MS):148[M]+。
3-甲基苯并[1,2-b]呋喃-4,5-二酮(6a)的制备
将化合物5a(300mg,2.03mmol)溶于10mL丙酮中,并将此溶液用冰浴冷却至0℃。将新鲜重结晶制备的费米盐1.8g溶于磷酸二氢钾缓冲液(0.07M KH2PO4溶于100mL水中,调PH值至7.0)中,同样将此溶液用冰浴冷却至0℃。取冷却的费米盐溶液逐滴加入到反应液中。此过程要缓慢,控制温度一直维持在0℃。在滴加过程中,溶液慢慢变为暗红色。滴加完毕后,溶液继续在冰浴下搅拌1h。此时溶液中会出现不溶性物质。将此红色固体物质过滤水洗后收集,即为3-甲基苯并[1,2-b]呋喃-4,5-二酮。得到红色固体(220mg,67%)。m.p.170-172℃,1H NMR(300MHz,CDCl3)δ:7.27(s,1H),7.24(d,J=10.3Hz,1H),6.12(d,J=10.3Hz,1H),2.24(s,3H);m/z(EI-MS):162[M]+。
3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮(7a)的制备
将6a(109mg,0.676mmol)溶于20mL甲苯溶液中,加入二氯二氰基苯醌(DDQ,153mg,0.676mmol)及2,3-二甲基-1,3-丁二烯(0.15mL,1.35mmol),氮气保护下冷凝回流反应40h,反应结束后,通过柱层析(PE:EA=20:1)分离纯化得红色目标物(30mg,20%)。m.p.180-182℃,1H NMR(300MHz,CDCl3)δ:7.84(s,1H),7.45(s,1H),7.23(s,1H),2.38(s,3H),2.33(s,3H),2.29(s,3H);m/z(EI-MS):m/z(EI-MS):240[M]+。
2-氯甲基-3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮(8a)的制备
将7a(50mg,0.208mmol)溶于饱和氯化氢的乙酸乙酯溶液中(20mL),于55℃下反应8h,反应结束后,将反应液倒入饱和碳酸氢钠水溶液中,洗去氯化氢,再用乙酸乙酯(20mL×3)萃取,无水硫酸钠干燥,减压除去乙酸乙酯后,得红色固体,无需进一步纯化,直接投下一步反应。m.p.158-160℃,1H NMR(300MHz,CDCl3)δ:7.84(s,1H),7.50(s,1H),4.64(s,2H),2.38(s,3H),2.33(s,3H),2.31(s,3H);m/z(EI-MS):288[M]+。
化合物CPUYB001的制备
将吗啉(0.46mmol),碘化钾(10mg,0.06mmol)以及碳酸钾(50mg,0.38mmol)溶于N,N-二甲基甲酰胺中(5mL),向反应液中加入8a(100mg,0.38mmol)。反应液于55℃下反应1h。冷却后,将反应也倒入冰水中,用乙酸乙酯萃取,饱和食盐水洗,无水硫酸钠干燥,过滤浓缩后得红色目标物CPUYB001(57mg,45%)。m.p.181-182℃,1H NMR(300MHz,CDCl3)δ:7.84(s,1H),7.51(s,1H),3.76(s,4H),3.57(s,2H),2.57(s,4H),2.37(s,3H),2.32(s,3H),2.30(s,3H).m/z(EI-MS):339[M]+,ESI-HRMS m/z[M+Na]+calculated for C20H21NO4Na:362.1363,found:362.1372。
实施例2
化合物CPUYB002的制备
用哌啶(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB002(38mg,30%)。m.p.166-167℃,1H NMR(300MHz,CDCl3)δ:7.83(s,1H),7.52(s,1H),3.62(s,2H),2.54(s,4H),2.37(s,3H),2.33(s,3H),2.29(s,3H),1.67(s,4H),1.48(s,2H).ESI-HRMS m/z[M+H]+calculated for C20H24NO3:338.1751,found:338.1760。
实施例3
化合物CPUYB003的制备
用4-甲基哌嗪(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB003(52mg,39%)。m.p.152-153℃,1H NMR(300MHz,CDCl3)δ:7.81(s,1H),7.48(s,1H),3.60(s,2H),2.64(s,8H),2.38(s,3H),2.35(s,3H),2.31(s,3H),2.25(s,3H).ESI-HRMS m/z[M+H]+C21H25N2O3:353.1860,found:353.1873。
实施例4
化合物CPUYB004的制备
用4-乙基哌嗪(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB004(49mg,35%)。m.p.155-157℃,1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.50(s,1H),3.62(s,2H),2.66(s,8H),2.49(s,2H),2.37(s,3H),2.32(s,3H),2.27(s,3H),1.16(t,J=4.5Hz,3H).ESI-HRMS m/z[M+H]+C22H27N2O3:367.2016,found:367.2032。
实施例5
化合物CPUYB005的制备
用吡咯(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB005(39mg,32%)。m.p.150-151℃,1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.52(s,1H),3.69(s,2H),2.65(s,4H),2.36(s,3H),2.32(s,3H),2.28(s,3H),1.85(s,4H).ESI-HRMS m/z[M+H]+C20H22N2O3:324.1594,found:324.1609。
实施例6
化合物CPUYB006的制备
用4-羟乙基哌嗪(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB006(41mg,28%)。m.p.151-152℃,1H NMR(300MHz,CDCl3)δ:7.83(s,1H),7.50(s,1H),4.23(s,2H),3.63(s,2H),2.68(s,8H),2.38(s,3H),2.33(s,3H),2.28(s,2H),2.05(s,3H).ESI-HRMS m/z[M+H]+C22H27N2O4:383.1965,found:383.1963。
实施例7
化合物CPUYB007的制备
用甲胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB007(31mg,28%)。m.p.156-157℃,1H NMR(300MHz,CDCl3)δ:7.83(s,1H),7.53(s,1H),3.59(s,2H),2.39(s,3H),2.37(s,3H),2.33(s,3H),2.30(s,3H).ESI-HRMS m/z[M+H]+C18H20N O3:298.1438,found:298.1450。
实施例8
化合物CPUYB008的制备
用二乙胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB008(35mg,28%)。m.p.161-162℃,1H NMR(300MHz,CDCl3)δ:7.84(s,1H),7.50(s,1H),3.74(s,2H),2.69(s,4H),2.8(s,3H),2.34(s,3H),2.31(s,3H),1.19(s,6H).(m/z)EI-MS:325[M]+。
实施例9
化合物CPUYB009的制备
用对氟苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB009(28mg,20%)。黑红色固体。m.p.184-185℃,1H NMR(300MHz,CDCl3)δ:7.80(s,1H),7.40(s,1H),6.93(t,J=9Hz,2H),6.63-6.68(m,2H),4.29(s,2H),2.38(s,3H),2.30(s,3H),2.29(s,3H).ESI-HRMS m/z[M+Na]+C22H18FNO3Na:386.1163,found:386.1171。
实施例10
化合物CPUYB010的制备
用邻甲氧基苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB010(28mg,18%)。黑红色固体。m.p.190-191℃,1H NMR(300MHz,CDCl3)δ:7.80(s,1H),7.45(s,1H),6.81-6.90(m,4H),4.40(s,2H),3.86(s,3H),2.35(s,3H),2.31(s,3H),2.25(s,3H).ESI-HRMS m/z[M+H]+C23H21NO4Na:398.1363,found:398.1372。
实施例11
化合物CPUYB011的制备
用间氟苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB011(25mg,18%)。红色固体。m.p.180-181℃,1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.46(s,1H),7.19-7.21(m,1H),6.61-6.65(m,3H),4.37(s,2H),2.38(s,3H),2.33(s,3H),2.28(s,3H).ESI-HRMS m/z[M+Na]+C22H18FNO3Na:386.1163,found:386.1185。
实施例12
化合物CPUYB012的制备
用2-甲基-4-氟苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUY012(20mg,14%)。红色固体。m.p 188-189℃,1H NMR(300MHz,CDCl3)δ:7.81(s,1H),7.41(s,1H),6.75-6.88(m,3H),4.36(s,2H),2.35(s,3H),2.31(s,3H),2.26(s,3H),2.21(s,3H).m/z(EI-MS):377[M]+。
实施例13
化合物CPUYB013的制备
用2,4-二氯苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB013(30mg,19%)。红色固体。m.p.190-191℃,1H NMR(300MHz,CDCl3)δ:7.83(s,1H),7.43(s,1H),7.31(s,1H),7.17(d,J=7.2Hz,1H),6.77(d,J=7.2Hz,1H),4.41(s,2H),2.38(s,3H),2.33(s,6H).m/z(EI-MS):413[M]+。
实施例14
化合物CPUYB014的制备
用4-甲氧基苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB014(21mg,15%)。红色固体。m.p.190-191℃,1H NMR(300MHz,CDCl3)δ:7.80(s,1H),7.45(s,1H),6.90-6.81(m,4H),4.40(s,2H),3.86(s,3H),2.35(s,3H),2.31(s,3H),2.25(s,3H).m/z(EI-MS):375[M]+。
实施例15
化合物CPUYB015的制备
用对苯基哌嗪(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB015(61mg,32%)。红色固体。m.p.193-194℃,1H NMR(300MHz,CDCl3)δ:7.79(s,1H),7.39(s,1H),7.29-7.23(m,5H),3.68(s,4H),3.52(s,2H),2.49(s,4H),2.37(s,3H),2.31(s,3H),2.27(s,3H).m/z(EI-MS):414[M]+。
实施例16
化合物CPUYB016的制备
用对苄基哌嗪(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB016(55mg,28%)。红色固体。m.p.190-191℃,1H NMR(300MHz,CDCl3)δ:7.79(s,1H),7.39(s,1H),7.29-7.23(m,5H),4.36(s,2H),3.68(s,4H),3.52(s,2H),2.49(s,4H),2.37(s,3H),2.31(s,3H),2.27(s,3H).m/z(EI-MS):428[M]+。
实施例17
化合物CPUYB017的制备
用对氟苯基哌嗪(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB017(40mg,20%)。红色固体。m.p.196-198℃,1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.51(s,1H),6.99-6.85(m,4H),3.67(s,2H),3.17(s,4H),2.73(s,4H),2.36(s,3H),2.32(s,3H),2.30(s,3H).m/z(EI-MS):432[M]+。
实施例18
化合物CPUYB018的制备
用3-氯-4-氟苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB018(24mg,13%)。红色固体。m.p.196-198℃,1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.42(s,1H),7.01(d,J=8.8Hz,1H),6.79-6.76(m,1H),6.57-6.55(m,1H),4.30(s,2H),2.37(s,3H),2.33(s,6H).m/z(EI-MS):397[M]+。
实施例19
化合物CPUYB019的制备
用4-硝基苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB019(37mg,19%)。红色固体。m.p.196-198℃,1H NMR(300MHz,CDCl3)δ:7.78(s,1H),7.37(s,1H),7.30(d,J=8.8Hz,2H),6.60(d,J=8.8Hz,2H),4.29(s,2H),2.34(s,3H),2.33(d,J=2.6Hz,6H).m/z(EI-MS):390[M]+。
实施例20
化合物CPUYB020的制备
用2,4-二氟苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB020(40mg,23%)。红色固体。m.p.196-198℃,1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.43(s,1H),6.88-6.70(m,3H),4.34(s,2H),2.37(s,3H),2.32(d,J=2.7Hz,6H).m/z(EI-MS):381[M]+。
实施例21
化合物CPUYB021的制备
用4-腈基苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB021(37mg,22%)。红色固体。m.p.196-198℃,1H NMR(300MHz,CDCl3)δ:7.80(s,1H),7.47(s,1H),7.49(d,J=6.8Hz,2H),7.37(s,1H),6.70(d,J=6.8Hz,2H),4.37(d,J=5.3Hz,2H),2.35(s,3H),2.32(s,6H).m/z(EI-MS):370[M]+。
实施例22
化合物CPUYB022的制备
用3-甲氧基苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB022(41mg,24%)。红色固体。m.p.196-198℃,1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.47(s,1H),6.88(m,4H),4.33(s,2H),3.78(s,3H),2.35(s,3H),2.33(s,3H),2.26(s,3H).m/z(EI-MS):375[M]+。
实施例23
化合物CPUYB023的制备
用3,4-二氯苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB023(38mg,20%)。红色固体。m.p.196-198℃,1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.41(s,1H),7.24(s,1H),6.84(d,J=2.5Hz,1H),6.57-6.54(m,1H),4.30(s,2H),4.14(brs,1H),2.37(s,3H),2.33(s,6H).m/z(EI-MS):413[M]+。
实施例24
化合物CPUYB024的制备
用4-吗啉甲基-苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB024(35mg,17%)。红色固体。m.p.180-181℃.1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.43(s,1H),7.18(d,J=8.4Hz,2H),6.69(d,J=8.4Hz,2H),4.43(s,2H),3.74-3.70(m,4H),3.42(s,2H),2.44-2.39(m,4H),2.36(s,3H),2.32(s,3H),2.28(s,3H).m/z(EI-MS):444[M]+。
实施例25
化合物CPUYB025的制备
用4-对乙基哌嗪基甲基-苯胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB025(65mg,30%)。红色固体。m.p.180-181℃.1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.46(s,1H),7.07(d,J=6.6Hz,2H),6.55(d,J=6.6Hz,2H),4.38(s,2H),3.18(s,4H),2.48-2.52(m,4H),2.35-2.38(m,7H),2.31(s,3H),2.26(s,3H),2.21(s,3H),1.02(t,J=7.8Hz,3H).m/z(EI-MS):471[M]+。
实施例26
化合物CPUYB026的制备
用4-氟苄胺(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB026(31mg,18%)。红色固体。m.p.180-181℃.1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.46(s,1H),7.35-7.28(m,2H),7.04(t,J=8.5Hz,2H),3.81(s,4H),2.37(s,3H),2.32(s,3H),2.21(s,3H).m/z(EI-MS):377[M]+。
实施例27
化合物CPUYB027的制备
用4-异丁醇(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB027(35mg,22%)。红色固体。m.p.162-163℃.1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.46(s,1H),3.90(m,2H),2.37(s,3H),2.34(s,3H),1.93-1.89(m,1H),0.91(s,6H).m/z(EI-MS):312[M]+。
实施例28
化合物CPUYB028的制备
用4-氟苯酚(0.46mmol)代替吗啉,以与化合物CPUYB001相同的方法合成化合物CPUYB026(25mg,15%)。红色固体。m.p.180-181℃.1H NMR(300MHz,CDCl3)δ:7.80(s,1H),7.40(s,1H),6.93(t,J=9Hz,2H),6.63-6.68(m,2H),5.17(s,2H),2.38(s,3H),2.30(s,3H),2.29(s,3H).m/z(EI-MS):364[M]+。
实施例29
(E)-4-(丁-1-烯基)吗啉(3b)的制备
丁醛(9.2mL,0.125mol)代替丙醛,以与化合物3a相同的方法合成无色油状液体3b(8.47g,48%)。1H NMR(300MHz,DMSO)δ:5.83(d,J=15Hz,1H),4.46-4.44(m,1H),3.65-3.55(m,4H),3.30-3.10(m,4H),2.14-2.00(m,2H),1.60-1.53(t,J=7.8Hz,3H);m/z(EI-MS):141[M]+。3-乙基-2-吗啉基-5-羟基-2,3-二氢苯并[1,2-b]呋喃(4b)的制备
用3b(6.5g,46.3mmol)代替3a,以与化合物4a相同的方法合成化合物4b(4.6g,36%)。3-乙基-5-羟基苯并[1,2-b]呋喃(5b)的制备
用4b代替4a外,以与化合物5a相同的方法合成化合物5b。白色晶体(2.3g,78%)。m.p.148-149℃,1H NMR(300MHz,CDCl3)δ:7.83(s,1H),7.49(d,J=8.8Hz,1H),6.80(d,J=2.7Hz,1H),6.77(dd,J=8.8,2.7Hz,1H),4.84(s,1H),2.60(q,J=7.8Hz,2H),1.25(s,3H);m/z(EI-MS):162[M]+。
3-乙基苯并[1,2-b]呋喃-4,5-二酮(6b)的制备
用5b代替5a外,以与化合物6a相同的方法合成化合物6b。红色固体(230mg,70%)。m.p.174-175℃,1H NMR(300MHz,CDCl3)δ:7.47(s,1H),7.34(d,J=10.3Hz,1H),6.22(d,J=10.3Hz,1H),2.60(q,J=7.8Hz,2H),1.24(s,3H);m/z(EI-MS):176[M]+。
3-乙基-7,8-二甲基萘[1,2-b]呋喃-4,5-二酮(7b)的制备
用6b代替6a外,以与化合物7a相同的方法合成化合物7b。为红色目标物(35mg,21%)。m.p.183-185℃,1H NMR(300MHz,CDCl3)δ:7.86(s,1H),7.54(s,1H),7.41(s,1H),2.38(s,3H),2.33(s,3H),2.29(q,J=6.9Hz,3H),1.25(t,J=6.9Hz,3H);m/z(EI-MS):m/z(EI-MS):254[M]+。
2-氯甲基-3-乙基-7,8-二甲基萘[1,2-b]呋喃-4,5-二酮(8b)的制备
用7b代替7a外,以与化合物8a相同的方法合成化合物8b。m.p.156-157℃,1H NMR(300MHz,CDCl3)δ:7.84(s,1H),7.54(s,1H),4.49(s,2H),2.62(q,J=7.8Hz,2H),2.33(s,3H),2.31(s,3H),1.25(t,J=7.8Hz,3H);m/z(EI-MS):302[M]+。
化合物CPUYB029的制备
将吗啉(0.46mmol),碘化钾(10mg,0.06mmol)以及碳酸钾(50mg,0.38mmol)溶于N,N-二甲基甲酰胺中(5mL),向反应液中加入2-氯甲基-3-乙基-7,8-二甲基萘[1,2-b]呋喃-4,5-二酮8b(100mg,0.38mmol)。反应液于55℃下反应1h。冷却后,将反应也倒入冰水中,用乙酸乙酯萃取,饱和食盐水洗,无水硫酸钠干燥,过滤浓缩后得红色目标物CPUYB001(57mg,45%)。m.p.181-182℃,1H NMR(300MHz,CDCl3)δ:7.84(s,1H),7.51(s,1H),3.76(s,4H),3.57(s,2H),2.60(q,J=7.8Hz,2H),2.57(s,4H),2.37(s,3H),2.32(s,3H),2.30(t,J=7.8Hz,3H).m/z(EI-MS):353[M]+,ESI-HRMS m/z[M+Na]+calculated for C21H23NO4Na:376.1519,found:376.1523。
实施例30
化合物CPUYB030的制备
用4-氟苯胺(0.46mmol)代替吗啉,以与化合物CPUYB029相同的方法合成化合物CPUYB030(31mg,18%)。红色固体。m.p.186-187℃,1H NMR(300MHz,CDCl3)δ:7.80(s,1H),7.40(s,1H),6.93(t,J=9Hz,2H),6.63-6.68(m,2H),4.29(s,2H),2.60(q,J=7.8Hz,2H),2.38(s,3H),2.30(s,3H),2.29(t,J=7.8Hz,3H).ESI-HRMS m/z[M+Na]+C23H20FNO3Na:400.1319,found:400.1322.
实施例31
(E)-4-(戊-1-烯基)吗啉(3c)的制备
用戊醛(9.5mL,0.125mol)代替丙醛,以与化合物3a相同的方法合成无色油状液体3c(9.43g,49%)。1H NMR(300MHz,DMSO)δ:5.84(d,J=15Hz,1H),4.55-4.44(m,1H),3.65-3.50(m,4H),3.35-3.30(m,4H),2.14-2.00(m,2H),1,46-1.40(m,2H),0.90(t,J=7.8Hz,3H);m/z(EI-MS):155[M]+。
3-丙基-2-吗啉基-5-羟基-2,3-二氢苯并[1,2-b]呋喃(4c)的制备
用3c(7.2g,46.3mmol)代替3a,以与化合物4a相同的方法合成化合物4c(4.9g,40%)。3-丙基-5-羟基苯并[1,2-b]呋喃(5c)的制备
用4c代替4a,以与化合物5a相同的方法合成化合物5c。白色絮状物(1.20g,40%)。m.p.149-151℃,1H NMR(300MHz,CDCl3)δ:7.83(s,1H),7.49(d,J=8.8Hz,1H),6.80(d,J=2.7Hz,1H),6.77(dd,J=8.8,2.7Hz,1H),5.35(s,1H),2.62(q,J=7.8Hz,2H),1.65-1.60(m,2H),1.11-0.90(M,3H);m/z(EI-MS):176[M]+。
3-丙基苯并[1,2-b]呋喃-4,5-二酮(6c)的制备
用5c代替5a,以与化合物6a相同的方法合成化合物6c。红色固体(174mg,45%)。m.p.177-178℃,1H NMR(300MHz,CDCl3)δ:7.46(s,1H),7.37(d,J=10.3Hz,1H),6.24(d,J=10.3Hz,1H),2.62(q,J=7.8Hz,2H),1.65-1.60(m,2H),0.90-0.85(m,3H);m/z(EI-MS):190[M]+。
3-丙基-7,8-二甲基萘[1,2-b]呋喃-4,5-二酮(7c)的制备
用6c代替6a,以与化合物7a相同的方法合成化合物7c。为红色目标物(45mg,25%)。m.p.184-186℃,1H NMR(300MHz,CDCl3)δ:7.86(s,1H),7.54(s,1H),7.41(s,1H),2.38(s,3H),2.33(s,3H),2.62(t,J=6.9Hz,3H),1.65-1.60(m,2H),0.90(t,J=6.9Hz,3H);m/z(EI-MS):m/z(EI-MS):268[M]+。
2-氯甲基-3-丙基-7,8-二甲基萘[1,2-b]呋喃-4,5-二酮(8c)的制备
用7c代替7a,以与化合物8a相同的方法合成化合物8c。m.p.159-160℃,1H NMR(300MHz,CDCl3)δ:7.86(s,1H),7.54(s,1H),4.49(s,2H),2.62(q,J=7.8Hz,2H),2.33(s,3H),2.31(s,3H),1.65-1.61(m,2H),0.90(t,J=7.8Hz,3H);m/z(EI-MS):302[M]+。
化合物CPUYB031的制备
将吗啉(0.46mmol),碘化钾(10mg,0.06mmol)以及碳酸钾(50mg,0.38mmol)溶于DMF中(5mL),向反应液中加入2-氯甲基-3-丙基-7,8-二甲基萘[1,2-b]呋喃-4,5-二酮8c(100mg,0.38mmol)。反应液于55℃下反应1h。冷却后,将反应也倒入冰水中,用乙酸乙酯萃取,饱和食盐水洗,无水硫酸钠干燥,过滤浓缩后得红色目标物CPUYB0031(57mg,45%)。m.p.181-182℃,1H NMR(300MHz,CDCl3)δ:7.84(s,1H),7.51(s,1H),3.76(s,2H),3.65-3.57(m,4H),2.62(t,J=7.8Hz,2H),2.57(m,4H),2.37(s,3H),2.32(s,3H),1.65(m,2H),0.90(t,J=7.8Hz,3H).ESI-HRMS m/z[M+Na]+calculated for C21H23NO4Na:390.1676,found:390.1670。
实施例32
(E)-4-(己-1-烯基)吗啉(3d)的制备
用己醛(9.8mL,0.125mol)代替丙醛,以与化合物3a相同的方法合成无色油状液体3d(6.21g,32%)。1H NMR(300MHz,DMSO)δ:5.84(d,J=15Hz,1H),4.50-4.44(m,1H),3.65-3.50(m,4H),3.34-3.30(m,4H),2.18-2.10(m,2H),1,36-1.31(m,2H),0.96-0.90(m,3H);m/z(EI-MS):169[M]+。
3-丁基-2-吗啉基-5-羟基-2,3-二氢苯并[1,2-b]呋喃(4d)的制备
用3d(7.8g,46.3mmol)代替3a,以与化合物4a相同的方法合成化合物4d(4.9g,38%)。3-丁基-5-羟基苯并[1,2-b]呋喃(5d)的制备
用4d代替4a,以与化合物5a相同的方法合成化合物5d。白色絮状物(1.13g,35%)。m.p.154-156℃,1H NMR(300MHz,CDCl3)δ:7.83(s,1H),7.49(d,J=8.8Hz,1H),6.80(d,J=2.7Hz,1H),6.77(dd,J=8.8,2.7Hz,1H),5.35(s,1H),2.62(q,J=7.8Hz,2H),1.65-1.60(m,2H),1.34-1.30(m,2H),1.11-0.90(M,3H);m/z(EI-MS):190[M]+。
3-丁基苯并[1,2-b]呋喃-4,5-二酮(6d)的制备
用5d代替5a,以与化合物6a相同的方法合成化合物6d。红色固体(157mg,38%)。m.p.155-157℃,1H NMR(300MHz,CDCl3)δ:7.46(s,1H),7.37(d,J=10.3Hz,1H),6.24(d,J=10.3Hz,1H),2.62(q,J=7.8Hz,2H),1.65-1.60(m,2H),1.31-1.27(m,2H),0.90-0.85(m,3H);m/z(EI-MS):204[M]+。
3-丁基-7,8-二甲基萘[1,2-b]呋喃-4,5-二酮(7d)的制备
用6d代替6a,以与化合物7a相同的方法合成化合物7d。为红色目标物(51mg,27%)。m.p.179-180℃,1H NMR(300MHz,CDCl3)δ:7.86(s,1H),7.54(s,1H),7.41(s,1H),2.38(s,3H),2.33(s,3H),2.62(t,J=6.9Hz,3H),1.65-1.60(m,2H),1.34-1.30(m,2H),0.90(t,J=6.9Hz,3H);m/z(EI-MS):m/z(EI-MS):282[M]+。
2-氯甲基-3-丁基-7,8-二甲基萘[1,2-b]呋喃-4,5-二酮(8d)的制备
用7d代替7a,以与化合物8a相同的方法合成化合物8d。m.p.151-152℃,1H NMR(300MHz,CDCl3)δ:7.86(s,1H),7.54(s,1H),4.49(s,2H),2.62(q,J=7.8Hz,2H),2.33(s,3H),2.31(s,3H),1.65-1.61(m,2H),1.33-1.31(m,2H),0.90(t,J=7.8Hz,3H);m/z(EI-MS):330[M]+。
化合物CPUYB032的制备
用4-对甲基哌嗪基甲基-苯胺(0.46mmol)代替吗啉,以与化合物CPUYB031相同的方法合成化合物CPUYB032(28mg,13%)。红色固体。m.p.180-181℃.1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.46(s,1H),7.07(d,J=6.6Hz,2H),6.55(d,J=6.6Hz,2H),4.38(s,2H),3.18(s,4H),2.62(m,2H),2.48-2.52(m,4H),2.35-2.38(m,7H),2.31(s,3H),2.26(s,3H),2.21(s,3H),1.59(m,2H),1.31(m,2H),1.02(t,J=7.8Hz,3H).m/z(EI-MS):499[M]+。
实施例33
2-氯甲酰基-3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮8e的制备
将上步化合物3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮7a(50mg,0.208mmol)溶于二氯甲烷溶液中(20mL),冰浴下滴加氯甲酰氯,滴加完毕后室温搅拌1h,反应结束后,将反应液倒入冰水中,再用乙酸乙酯(20mL×3)萃取,无水硫酸钠干燥,减压除去乙酸乙酯后,得红色固体。m.p.150-152℃1H NMR(300MHz,CDCl3)δ:7.84(s,1H),7.50(s,1H),4.64(s,2H),2.38(s,3H),2.33(s,3H),2.51(s,3H);m/z(EI-MS):302[M]+。
化合物CPUYB033的制备
将4-氟苯胺(0.46mmol),碘化钾(10mg,0.06mmol)以及碳酸钾(50mg,0.38mmol)溶于DMF中(5mL),向反应液中加入2-氯甲酰基-3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮8e(100mg,0.38mmol)。反应液于55℃下反应1h。冷却后,将反应也倒入冰水中,用乙酸乙酯萃取,饱和食盐水洗,无水硫酸钠干燥,过滤浓缩后得红色目标物CPUYB0033(57mg,45%)。m.p.172-174℃,1H NMR(300MHz,CDCl3)δ:7.80(s,1H),7.40(s,1H),6,93(t,J=9Hz,2H),6.63-6,68(m,2H),2.38(s,3H),2.30(s,3H),2.29(s,3H).m/z(EI-MS):377[M]+。
实施例34
化合物CPUYB034的制备
用4-氟苄胺(0.15mmol)代替4-氟苯胺,以与化合物CPUYB033相同的方法合成化合物CPUYB034(21mg,38%)。红色固体。m.p.190-191℃,1H NMR(300MHz,CDCl3)δ:7.88(s,1H),7.50(s,1H),7.43-7.38(m,2H),7.10(t,J=8.6Hz,2H),6.71(brs,1H),4.66(d,J=6.1Hz,2H),2.71(s,3H),2.40(s,3H),2.36(s,3H).m/z(EI-MS):391[M]+。
实施例35
化合物CPUYB035的制备
用4-(二羟乙基胺基-1-甲基)苯胺(0.15mmol)代替4-氟苯胺,以与化合物CPUYB033相同的方法合成化合物CPUYB035(27mg,41%)。红色固体。m.p.179-181℃,1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.46(s,1H),7.07(d,J=6.6Hz,2H),6.55(d,J=6.6Hz,2H),3.66(s,2H),3.45(t,J=8.1Hz,4H),2.53(t,J=8.1Hz,4H),2.31(s,3H),2.26(s,3H),2.21(s,3H).m/z(EI-MS):476[M]+.
实施例36
2-氯乙酰基-3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮8f的制备
用氯乙酰氯代替氯甲酰氯外,以与化合物8e相同的方法合成化合物8f。m.p.151-152℃,1H NMR(300MHz,CDCl3)δ:7.86(s,1H),7.54(s,1H),4.83(s,2H),2.52(s,3H),2.33(s,3H),2.31(s,3H);m/z(EI-MS):316[M]+。
化合物CPUYB036的制备
将4-氟苯胺(0.46mmol),碘化钾(10mg,0.06mmol)以及碳酸钾(50mg,0.38mmol)溶于DMF中(5mL),向反应液中加入2-氯乙酰基-3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮8f(120mg,0.38mmol)。反应液于55℃下反应1h。冷却后,将反应也倒入冰水中,用乙酸乙酯萃取,饱和食盐水洗,无水硫酸钠干燥,过滤浓缩后得红色目标物CPUYB0036(57mg,45%)。m.p.172-174℃,1H NMR(300MHz,CDCl3)δ:7.80(s,1H),7.40(s,1H),6.93(t,J=9Hz,2H),6.63-6,68(m,2H),4.74(s,2H),2.38(s,3H),2.30(s,3H),2.29(s,3H).m/z(EI-MS):391[M]+。
实施例37
2-氯丙酰基-3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮(8g)的制备
用氯丙酰氯代替氯甲酰氯,以与化合物8e相同的方法合成化合物8g。m.p.161-162℃,1H NMR(300MHz,CDCl3)δ:7.88(s,1H),7.55(s,1H),3.70(t,J=6.9Hz,2H),3.02(t,J=6.9Hz,2H),2.51(s,3H),2.34(s,3H);m/z(EI-MS):330[M]+。
化合物CPUYB037的制备
将4-氟苯胺(0.46mmol),碘化钾(10mg,0.06mmol)以及碳酸钾(50mg,0.38mmol)溶于DMF中(5mL),向反应液中加入2-氯丙酰基-3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮8g(125mg,0.38mmol)。反应液于55℃下反应1h。冷却后,将反应也倒入冰水中,用乙酸乙酯萃取,饱和食盐水洗,无水硫酸钠干燥,过滤浓缩后得红色目标物CPUYB0037(69mg,45%)。m.p.172-174℃,1H NMR(300MHz,CDCl3)δ:7.80(s,1H),7.40(s,1H),6.93(t,J=9Hz,2H),6.63-6,68(m,2H),4.74(s,2H),3.40-3.36(m,4H),2.38(s,3H),2.30(s,3H),2.29(s,3H).m/z(EI-MS):405[M]+。
实施例38
2-氯磺酰基-3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮(8h)的制备
将3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮7a(50mg,0.208mmol)溶于二氯甲烷溶液中(20mL),冰浴下滴加氯磺酸,滴加完毕后室温搅拌2h,反应结束后,将反应液倒入冰水中,再用乙酸乙酯(20mL×3)萃取,无水硫酸钠干燥,减压除去乙酸乙酯后,得红色固体。m.p.150-152℃,1H NMR(300MHz,CDCl3)δ:7.84(s,1H),7.50(s,1H),2.38(s,3H),2.33(s,3H),1.39(s,3H);m/z(EI-MS):338[M]+。
化合物CPUYB038的制备
将吗啉(0.46mmol),KI(10mg,0.06mmol)以及碳酸钾(50mg,0.38mmol)溶于DMF中(5mL),向反应液中加入2-氯甲磺酰基-3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮8h(0.38mmol)。反应液于55℃下反应1h。冷却后,将反应也倒入冰水中,用乙酸乙酯萃取,饱和食盐水洗,无水硫酸钠干燥,过滤浓缩后得红色目标物CPUYB038(66mg,45%)。m.p.176-177℃.1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.46(s,1H),3.51-3.65(m,8H),2.39(s,3H),2.34(s,3H),2.30(s,3H).m/z(EI-MS):389[M]+。
实施例39
化合物CPUYB039的制备
用4-氟苯胺(0.46mmol)代替吗啉,以与化合物CPUYB038相同的方法合成化合物CPUYB039(45mg,29%).m.p.172-174℃,1H NMR(300MHz,CDCl3)δ:7.80(s,1H),7.40(s,1H),6,92(t,J=6.99Hz,2H),6.63-6,68(m,2H),2.37(s,3H),2.30(s,3H),2.28(s,3H).m/z(EI-MS):413[M]+。
实施例40
2-氯甲磺酰基-3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮(8i)的制备
将3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮7a(50mg,0.208mmol)溶于二氯甲烷溶液中(20mL),冰浴下滴加氯磺酸,滴加完毕后室温搅拌2h,反应结束后,将反应液倒入冰水中,再用乙酸乙酯(20mL×3)萃取,无水硫酸钠干燥,减压除去乙酸乙酯后,得红色固体。m.p.150-152℃,1H NMR(300MHz,CDCl3)δ:7.84(s,1H),7.50(s,1H),2.38(s,3H),2.33(s,3H),1.39(s,3H);m/z(EI-MS):338[M]+。
化合物CPUYB040的制备
用4-(4-甲基哌嗪-1-甲基)苯胺(0.46mmol)代替吗啉,8i代替8h,以与化合物CPUYB038相同的方法合成化合物CPUYB040(62mg,38%)。红色固体。m.p.190-191℃,1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.47(s,1H),6.69(s,2H),6.42(s,2H),3.66(s,2H),3.64(m,2H),3.44(s,4H),2.36(s,4H),2.38(s,3H),2.34(s,3H),2.32(s,3H),2.26(s,3H).m/z(EI-MS):521[M]+。
实施例41
2-氯乙磺酰基-3,7,8-三甲基萘[1,2-b]呋喃-4,5-二酮8j的制备
用氯乙磺酸替氯磺酸,以与化合物8g相同的方法合成化合物8j。m.p.161-162℃,1H NMR(300MHz,CDCl3)δ:7.88(s,1H),7.55(s,1H),5.12(s,2H),2.36(s,3H),2.34(s,3H),1.93(s,3H);m/z(EI-MS):352[M]+。
化合物CPUYB041的制备
用4-(二羟乙基胺基-1-甲基)苯胺(0.46mmol)代替吗啉,用8i代替8f,以与化合物CPUYB038相同的方法合成化合物CPUYB041(67mg,41%)。红色固体。m.p.179-181℃,1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.46(s,1H),7.07(d,J=6.6Hz,2H),6.55(d,J=6.6Hz,2H),3.64(m,2H),3.62(s,2H),3.45(t,J=8.1Hz,4H),2.53(t,J=8.1Hz,4H),2.31(s,3H),2.26(s,3H),2.21(s,3H).m/z(EI-MS):540[M]+。
实施例42
通式I化合物合成路线(B系列化合物的合成):
化合物(9)的制备
将化合物1(2.9mmol)溶于THF/H2O中,将用水溶解的叠氮化钠(0.625g,8.7mmol)逐滴加入到反应液中,室温搅拌反应,TLC板监控反应,反应结束后将反应液倒入水中,再用乙酸乙酯萃取,饱和碳酸钠洗,无水硫酸钠干燥,旋干得粗品,用乙醇重结晶最终得橘黄色固体9(380mg,76%).m.p.75-76℃,1H NMR(300MHz,CDCl3)δ:6.83(s,2H),5.52(s,1H).m/z(EI-MS):123[M]+。
化合物(10)的制备
将化合物9(0.58mmol)溶解于醋酸中,将溶有溴化氢(0.058mmol)和氯乙醛(2.9mmol)的醋酸溶液滴加到反应液中,室温搅拌反应,TLC监控反应,反应结束后将反应液倒入水中,用乙酸乙酯萃取,有机层用碳酸氢钠洗,饱和氯化钠洗,无水硫酸钠干燥,旋干,得粗品,用二氯甲烷重结晶,得粉红色固体13(50mg,47%)。m.p.110-111℃.1H NMR(300MHz,CDCl3)δ:7.62(d,J=4.4Hz,1H),6.95(d,J=4.4Hz,1H),6.73(s,1H),5.11(s,2H).m/z(EI-MS):183[M]+。
化合物(11)的制备
将化合物10(0.23mmol)溶于适量丙酮中,溶有费米盐(0.70mmol)的磷酸二氢钾水溶液缓慢滴加到反应液中,室温搅拌,TLC板监控,反应结束后,略微旋去丙酮,有固体析出,将固体抽滤出来得红色固体11(26mg,57.8%)。m.p.140-141℃.1H NMR(300MHz,CDCl3)δ:7.39(d,J=9.0Hz,1H),6.24(d,J=9.0Hz,1H),5.09(s,2H).m/z(EI-MS):196[M]+。
化合物(12)的制备
将化合物11(0.676mmol)溶于20mL甲苯溶液中,加入二氯二氰基苯醌(DDQ,0.676mmol)及2,3-二甲基-1,3-丁二烯(0.15mL,1.35mmol),氮气保护下冷凝回流反应10h,反应结束后,通过柱层析(PE:EA=20:1)分离纯化得红色目标物12(30mg,20%)。m.p.170-172℃,1H NMR(300MHz,CDCl3)δ:7.84(s,1H),7.55(s,1H),5.11(s,2H),2.34(s,3H),2.33(s,3H).m/z(EI-MS):275[M]+。
化合物CPUYB042的制备
将二甲胺(0.46mmol),KI(10mg,0.06mmol)以及碳酸钾(50mg,0.38mmol)溶于DMF(5mL)中,向反应液中加入12(0.38mmol)。反应液于55℃下反应2h。冷却后,将反应也倒入冰水中,用乙酸乙酯萃取,饱和食盐水洗,无水硫酸钠干燥,过滤浓缩后得红色目标物CPUYB042(56mg,45%)。m.p.181-182℃,1H NMR(300MHz,CDCl3)δ:7.83(s,1H),7.53(s,1H),3.59(s,2H),2.45(s,6H),2.33(s,3H),2.30(s,3H),m/z(EI-MS):284[M]+。
实施例43
化合物CPUYB043的制备
用吗啉(0.46mmol)代替二甲胺,以与化合物CPUYB042相同的方法合成化合物CPUYB043(38mg,31%)。m.p.156-157℃,1H NMR(300MHz,CDCl3)δ:7.84(s,1H),7.51(s,1H),3.84(s,2H),3.74(s,4H),2.65(s,4H),2.32(s,3H),2.30(s,3H).m/z(EI-MS):326[M]+。
实施例44
化合物CPUYB044的制备
用间氟苯胺(0.46mmol)代替二甲胺,以与化合物CPUYB042相同的方法合成化合物CPUYB044(27mg,20%)。黑红色固体。m.p.182-184℃,1H NMR(300MHz,CDCl3)δ:7.84(s,1H),7.40(s,1H),7.11-7.05(m,1H),6.79(t,J=6.6Hz,1H),6.52(d,J=7.8Hz,1H),6.35(t,J=9.5Hz,1H),4.60(d,J=6.3Hz,2H).,2.30(s,3H),2.29(s,3H).m/z(EI-MS):350[M]+。
实施例45
化合物CPUYB045的制备
用对苄基哌嗪(0.46mmol)代替二甲胺,以与化合物CPUYB042相同的方法合成化合物CPUYB045(65mg,41%)。黑红色固体。m.p.168-169℃,1H NMR(300MHz,CDCl3)δ:7.82(s,1H),7.41(s,1H),7.44-7.28(m,5H),3.88(s,2H),3.61(s,2H),2.75-2.51(m,8H),2.30(s,3H),2.29(s,3H).m/z(EI-MS):415[M]+。
实施例46
化合物CPUYB046的制备
用对氟苯酚(0.46mmol)代替二甲胺,以与化合物CPUYB042相同的方法合成化合物CPUYB046(27mg,34%)。黑红色固体。m.p.172-174℃,1H NMR(300MHz,CDCl3)δ:7.80(s,1H),7.40(s,1H),7.33-7.23(m,4H),5.38(s,2H),2.30(s,3H),2.29(s,3H).m/z(EI-MS):351[M]+。
Claims (8)
1.通式(I)的邻萘醌化合物或其药学上可接受的盐:
其中X代表碳原子或氮原子;当X为氮原子时,R1无取代;当X为碳原子时,R1为氢、或C1~C4烷基;
L代表-(CH2)n-,其中n为1~2;或L代表-CO(CH2)n–、-SO2(CH2)n-,其中n为0~2;
R2代表C1~C4烷氧基、-NRaRb、 m代表0或1;Ar代表苯环及或5~6员芳杂环;R4代表氢、卤素、氰基、硝基、甲氧基、C1~C4烷基、-NRaRb或-CH2-NRaRb;
上述-NRaRb中的Ra、Rb各自独立代表氢、C1~C4烷基、C1~C4羟烷基或Ra、Rb连接形成5~6员含氮杂环。
2.权利要求1的化合物或其药学上可接受的盐,其中X为碳原子;R1代表甲基。
3.权利要求1的化合物或其药学上可接受的盐,其中L代表-CH2-、-CO-、-COCH2-或-SO2-。
4.权利要求1的化合物或其药学上可接受的盐,其中R2代表-NRaRb、 其中Ra、Rb、m、R4定义同权利要求1。
5.权利要求4的化合物或其药学上可接受的盐,其中R2代表-NRaRb,Ra、Rb各自独立代表氢、甲基、乙基、丙基、异丙基、正丁基;或者Ra、Rb连接形成四氢吡咯基、哌啶基、吗啡啉基、哌嗪基或N-甲基哌嗪基。
6.权利要求1的通式(I)化合物的制备方法,包括:
其中X、R1、R2、L的定义如同权利要求1。
7.一种药物组合物,其中含有权利要求1的化合物或其药学上可接受的盐及药学上可接受的载体。
8.权利要求1的化合物或其药学上可接受的盐用于制备治疗恶性肿瘤的药物的用途。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510553148.2A CN105130936B (zh) | 2015-09-01 | 2015-09-01 | 一类邻萘醌化合物、其制备方法和医药用途 |
PCT/CN2015/097157 WO2017035982A1 (zh) | 2015-09-01 | 2015-12-11 | 一类邻萘醌化合物、其制备方法和医药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510553148.2A CN105130936B (zh) | 2015-09-01 | 2015-09-01 | 一类邻萘醌化合物、其制备方法和医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105130936A CN105130936A (zh) | 2015-12-09 |
CN105130936B true CN105130936B (zh) | 2017-09-26 |
Family
ID=54716567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510553148.2A Active CN105130936B (zh) | 2015-09-01 | 2015-09-01 | 一类邻萘醌化合物、其制备方法和医药用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN105130936B (zh) |
WO (1) | WO2017035982A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105130936B (zh) * | 2015-09-01 | 2017-09-26 | 中国药科大学 | 一类邻萘醌化合物、其制备方法和医药用途 |
CN106117172B (zh) * | 2016-06-17 | 2018-08-07 | 中南大学 | 萘并[1,2-b]呋喃-4,5-二酮-2-磺酸衍生物及其盐在制备抗肿瘤药物上的应用 |
JP7007746B2 (ja) * | 2018-04-09 | 2022-01-25 | ヒュエン カンパニー リミテッド | 1,2-ナフトキノン誘導体化合物を含む固形癌または血液癌の予防または治療用薬学組成物 |
KR20190118118A (ko) | 2018-04-09 | 2019-10-17 | 영진약품 주식회사 | 1,2-나프토퀴논 유도체 화합물을 포함하는 고형암 또는 혈액암의 예방 또는 치료용 약학 조성물 |
CN109485646A (zh) * | 2018-12-12 | 2019-03-19 | 中国药科大学 | 一种苯并噻唑醌类化合物及其制备方法和用途 |
CN110156822B (zh) * | 2019-05-17 | 2021-07-09 | 中国药科大学 | 一种萘酚-苯硼酸类化合物及其制备方法和用途 |
CN112225713B (zh) * | 2020-11-16 | 2023-02-28 | 华东理工大学 | 一种5-羟基苯并呋喃类化合物的合成工艺 |
CN113121510B (zh) * | 2021-03-26 | 2023-04-14 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种萘并呋喃邻醌化合物及其制备方法和应用、抗肿瘤药物组合物、抗菌药物组合物 |
CN113773289B (zh) * | 2021-09-15 | 2023-05-12 | 沈阳药科大学 | 一种萘[1,2-b]杂环-4,5-二酮类化合物及其制备方法和应用 |
CN114195814B (zh) * | 2022-01-27 | 2023-07-21 | 中国药科大学 | 羟基萘酮-苯硼酸类化合物、制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5883270A (en) * | 1996-02-20 | 1999-03-16 | Wisconsin Alumni Research Foundation | 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth |
WO2008066301A1 (en) * | 2006-11-27 | 2008-06-05 | Mazence Inc. | Anticancer composition containing naphthoquinone-based compound for intestine delivery system |
CN101274925A (zh) * | 2007-03-29 | 2008-10-01 | 中国科学院上海药物研究所 | 一类萘并呋喃邻醌化合物及其制备方法和用途 |
KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
DK3091005T3 (da) * | 2013-12-30 | 2020-12-21 | Huen Co Ltd | 1,2-naphthoquinonderivat og fremgangsmåde til fremstilling deraf |
CN105130936B (zh) * | 2015-09-01 | 2017-09-26 | 中国药科大学 | 一类邻萘醌化合物、其制备方法和医药用途 |
-
2015
- 2015-09-01 CN CN201510553148.2A patent/CN105130936B/zh active Active
- 2015-12-11 WO PCT/CN2015/097157 patent/WO2017035982A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN105130936A (zh) | 2015-12-09 |
WO2017035982A1 (zh) | 2017-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105130936B (zh) | 一类邻萘醌化合物、其制备方法和医药用途 | |
Li et al. | Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease | |
Tandon et al. | Design, synthesis and biological evaluation of novel nitrogen and sulfur containing hetero-1, 4-naphthoquinones as potent antifungal and antibacterial agents | |
O’Boyle et al. | Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones | |
Xie et al. | Design, synthesis and biological evaluation of organophosphorous-homodimers as dual binding site acetylcholinesterase inhibitors | |
Tang et al. | Synthesis and evaluation of xanthine oxidase inhibitory and antioxidant activities of 2-arylbenzo [b] furan derivatives based on salvianolic acid C | |
Roma et al. | Coumarin, chromone, and 4 (3H)-pyrimidinone novel bicyclic and tricyclic derivatives as antiplatelet agents: synthesis, biological evaluation, and comparative molecular field analysis | |
Papadopoulou et al. | Novel 3-nitro-1H-1, 2, 4-triazole-based piperazines and 2-amino-1, 3-benzothiazoles as antichagasic agents | |
CN105566276B (zh) | 作为dpp-4抑制剂的苯并六元环衍生物及其应用 | |
Marvadi et al. | Synthesis of novel morpholine, thiomorpholine and N-substituted piperazine coupled 2-(thiophen-2-yl) dihydroquinolines as potent inhibitors of Mycobacterium tuberculosis | |
CN109320458A (zh) | 一类含二芳基咪唑类化合物及其制备方法和医药用途 | |
Horvath et al. | 2-(1-Adamantyl)-4-(thio) chromenone-6-carboxylic acids: potent reversible inhibitors of human steroid sulfatase | |
Patagar et al. | Synthesis, antioxidant and anti-diabetic potential of novel benzimidazole substituted coumarin-3-carboxamides | |
CN107459476A (zh) | 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途 | |
Lan et al. | Chromanones: selective and reversible monoamine oxidase B inhibitors with nanomolar potency | |
CN111747921A (zh) | 瑞香素衍生物制备方法及其医药用途 | |
CN105175360B (zh) | 醚类芳基哌嗪衍生物及其盐、制备方法和用途 | |
DE60309349T2 (de) | Propanamine derivate als serotonin und norepinephrin reuptake-inhibitoren | |
CN106831799A (zh) | 羟基苯乙烯吡啶曼尼希碱类化合物、其制备方法和用途 | |
CN110240559A (zh) | 2-(2,2-二芳基乙烯基)环胺衍生物及其制备方法 | |
CN106214677B (zh) | 一种含烯丙基取代的单羰基姜黄素类化合物在制备抗肿瘤药物中的应用 | |
CN108623537A (zh) | 含胺基侧链的芳香胺类乙酰胆碱酯酶抑制剂合成与用途 | |
CA2010217C (en) | Aralkylamine compounds | |
CN106883225B (zh) | 一种具有1,2,4-恶二唑-结构片段的香豆素衍生物及其应用 | |
CN111499608B (zh) | 苯并[c]苯并吡喃酮类衍生物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |